Figure 3
From: MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Nutlin-3a modulates MDM2-binding proteins in a p53-dependent manner. Cell lines were exposed to drug-free media (Ctrl), Nutlin-3a (N), Cisplatin (Cis), Doxorubicin (Dox), Methotrexate (Mtx), Nutlin-3a combined with Cisplatin (N:C), Doxorubicin (N:D) or Methotrexate (N:M) in 1:1 ratios. A and B illustrate the induction of p53 pathway components by N:C and N:D combinations in the two MDM2 Ampl cell lines OSA and T778. C U2OS (MDM2 Wt) displays specific reduction in MDM4 (62kDa) after Methotrexate exposure alone or in combination with Nutlin-3a. D and E display the TP53 Mut cell lines RMS13 and SaOS-2 respectively. The figure shows representative western blots of 3 independent biological experiments, targeting p53, p21, MDM2, MDM4, PUMA, and β-actin (loading control). Figure F illustrates quantitative measurements of the same three western blot experiments, values representing mean fold induction ranging from 0.8 (green) to 2.6 fold (red).